Description of Invention:
This invention includes the gene sequence for a novel proto-oncogene binding protein that is valuable for studying the regulation of genes responsible for transforming normal cells to cancer cells. The c-myc proto-oncogene plays a central role in normal cell proliferation and programmed cell death; factors that inhibit its expression thus contribute to the formation of a variety of tumors. This newly isolated gene sequence encodes a protein that binds to the far-upstream element (FUSE) of the c-myc gene, which has been shown to be required for its maximal transcription. The FUSE-binding protein gene sequence may be used to analyze mutations, translocations, and other genetic derangements that are associated with abnormalities of the FUSE protein or c-myc expression. Such DNA probes also may be useful for diagnosing a variety of physiologic and pathologic conditions, such as the transformation of normal cells to tumor cells. The FUSE-binding protein also may be used for developing mAbs that can be used to detect and quantitate the protein in biologic samples.
Inventors:
DL Levens (NCI) RC Duncan (NCI)
Patent Status:
DHHS Reference No. E-218-1992/0 --
U.S. Patent 5,580,760 issued 03 Dec 1996
U.S. Patent 5,734,016 issued 31 Mar 1998
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
